NYSE:AZN - AstraZeneca Stock Price, Forecast & News

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca declared a semi-annual dividend on Tuesday, February 18th. Investors of record on Friday, February 28th will be paid a dividend of $0.95 per share on Monday, March 30th. This represents a yield of 2.8%. The ex-dividend date is Thursday, February 27th. View AstraZeneca's Dividend History.

Shares of AstraZeneca split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were distributed to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) posted its quarterly earnings results on Friday, February, 14th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.53 by $0.08. The business had revenue of $6.66 billion for the quarter, compared to analysts' expectations of $6.75 billion. AstraZeneca had a net margin of 5.38% and a return on equity of 32.24%. The firm's revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Friday, April 24th 2020. View Earnings Estimates for AstraZeneca.

12 Wall Street analysts have issued 12-month price objectives for AstraZeneca's stock. Their forecasts range from $40.73 to $57.00. On average, they anticipate AstraZeneca's stock price to reach $50.68 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Price Targets for AstraZeneca.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Media headlines about AZN stock have trended very negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Sanofi (SNY), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), AT&T (T), AbbVie (ABBV), Bank of America (BAC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), Bristol-Myers Squibb (BMY) and Intel (INTC).

AstraZeneca's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (2.02%), Wealth Quarterback LLC (1.77%), Jennison Associates LLC (1.40%), Capital International Investors (0.87%), Bank of America Corp DE (0.35%) and GQG Partners LLC (0.27%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Marshall Wace North America L.P., Bank of America Corp DE, Marshall Wace LLP, Bank of Montreal Can, Schafer Cullen Capital Management Inc, Russell Investments Group Ltd. and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for AstraZeneca.

AZN stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Capital International Investors, FMR LLC, GQG Partners LLC, Renaissance Technologies LLC, Jennison Associates LLC, Galibier Capital Management Ltd. and Ariose Capital Management Ltd. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $47.08.

AstraZeneca has a market capitalization of $123.53 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]